Cirrhosis & Advanced Liver Disease Treatment in Dallas, TX

Medically reviewed by Jaison John, MD — Board-Certified Gastroenterologist
Last updated: March 2026

What Is Cirrhosis?

Cirrhosis is a late stage of progressive liver scarring (fibrosis) in which the liver's normal, soft tissue is gradually replaced by hard scar tissue. Over time, this scarring distorts the liver's internal architecture, impairs blood flow through the organ, and progressively diminishes the liver's ability to perform its more than 500 essential functions — including filtering toxins from the blood, producing proteins necessary for blood clotting and immune function, metabolizing medications, storing energy, and manufacturing bile to help digest fats.

Cirrhosis does not develop suddenly. It is the result of years to decades of chronic liver injury and inflammation caused by conditions such as excessive alcohol consumption, chronic viral hepatitis (hepatitis B or C), or metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as nonalcoholic fatty liver disease or NAFLD). As the liver repeatedly attempts to repair itself in response to ongoing damage, scar tissue accumulates. In the early stages, the liver can compensate for the scarring and continue to function relatively well. However, as more and more healthy liver cells are replaced by scar tissue, the liver eventually reaches a point where it can no longer keep up — a critical transition known as decompensation.

Cirrhosis is a significant public health concern. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), chronic liver disease and cirrhosis affect more than 4.5 million adults in the United States and account for approximately 56,000 deaths annually, making it the 9th leading cause of death. The burden of cirrhosis is increasing, driven largely by the rising prevalence of obesity-related fatty liver disease and continued impact of alcohol use.

At Texas Gut Health in Sachse, TX, Dr. Jaison John provides expert evaluation and long-term management for patients with cirrhosis throughout the Dallas-Fort Worth area. Dr. John completed his gastroenterology fellowship at UT Medical Branch, where he served as Chief Fellow, and his internal medicine residency at UT Austin Dell Medical School, where he served as Chief Resident. He holds dual board certifications from the American Board of Internal Medicine in both internal medicine and gastroenterology. His comprehensive approach includes identifying the underlying cause of liver disease, staging the severity of fibrosis, screening for complications, and coordinating with hepatology and liver transplant teams when advanced care is needed.

Symptoms of Cirrhosis

One of the most important things to understand about cirrhosis is that it is often "silent" in its early stages. Many patients with compensated cirrhosis have no symptoms at all and may be unaware they have the condition until it is detected through routine blood work, imaging, or an evaluation for another health concern. As liver function declines and portal hypertension (increased pressure in the blood vessels flowing to the liver) develops, symptoms and complications become increasingly apparent.

Early Symptoms (Compensated Cirrhosis)

• Fatigue and weakness — Persistent, unexplained tiredness is often the earliest and most common symptom of cirrhosis. It results from the liver's diminished ability to process nutrients, produce proteins, and clear metabolic waste products.
• Loss of appetite and weight loss — Reduced appetite, early satiety (feeling full quickly), nausea, and unintentional weight loss are common as liver function declines.
• Dull right upper abdominal discomfort — A vague ache or sense of fullness in the right upper abdomen, where the liver is located, may be present as the liver becomes enlarged or inflamed.
• Spider angiomas — Small, spider-like clusters of tiny blood vessels visible on the skin, particularly on the face, chest, and upper arms, are a classic sign of chronic liver disease.
• Palmar erythema — Redness of the palms, particularly at the base of the thumb and little finger, is caused by altered estrogen metabolism in the diseased liver.
• Easy bruising and prolonged bleeding — The liver produces clotting factors; as its synthetic function declines, patients bruise more easily and cuts may bleed longer than expected.

Late Symptoms (Decompensated Cirrhosis)

Decompensated cirrhosis is marked by the development of one or more serious complications that reflect the liver's inability to maintain essential functions:

• Jaundice — Yellowing of the skin and the whites of the eyes occurs when the liver can no longer adequately process bilirubin, a yellow pigment produced by the breakdown of red blood cells. Jaundice may also cause dark-colored urine and pale or clay-colored stools.
• Ascites — The accumulation of fluid in the abdominal cavity is one of the most common complications of decompensated cirrhosis, caused by a combination of portal hypertension, low albumin levels, and kidney sodium retention. Ascites causes abdominal swelling, discomfort, shortness of breath, and early satiety.
• Hepatic encephalopathy — When the scarred liver can no longer effectively filter ammonia and other toxins from the blood, these substances accumulate in the brain and cause a spectrum of neurological symptoms ranging from subtle cognitive changes (difficulty concentrating, forgetfulness, personality changes) to confusion, disorientation, severe drowsiness, and in extreme cases, coma.
• Variceal bleeding — Portal hypertension forces blood to find alternative routes around the scarred liver, causing veins in the esophagus and stomach (varices) to become enlarged and fragile. Ruptured varices can cause massive, life-threatening gastrointestinal bleeding with vomiting of blood (hematemesis) or passage of black, tarry stools (melena).
• Peripheral edema — Swelling in the legs and ankles due to low albumin levels and fluid retention.
• Muscle wasting (sarcopenia) — Progressive loss of muscle mass and strength is common in advanced cirrhosis and contributes to weakness, falls, and reduced quality of life.

Causes & Risk Factors

Cirrhosis is not a disease in itself but rather the end result of chronic, ongoing liver injury from a variety of causes. Identifying the specific cause is critical because treatment of the underlying condition can slow, halt, or in some cases partially reverse the progression of liver fibrosis.

Common Causes

• Alcohol-related liver disease (ALD) — Chronic heavy alcohol consumption is one of the leading causes of cirrhosis worldwide. The liver metabolizes alcohol, and excessive, prolonged intake causes a progression from fatty liver (steatosis) to alcoholic hepatitis to cirrhosis. The risk increases with the amount and duration of alcohol use, though individual susceptibility varies due to genetic and other factors. Women are more susceptible to alcohol-related liver damage than men at lower levels of consumption.
• Metabolic dysfunction-associated steatotic liver disease (MASLD) — Formerly known as nonalcoholic fatty liver disease (NAFLD), MASLD is now the fastest-growing cause of cirrhosis in the United States. It is closely associated with obesity, type 2 diabetes, metabolic syndrome, and insulin resistance. In MASLD, fat accumulates in the liver and triggers inflammation (steatohepatitis or MASH, formerly NASH), which over years can lead to progressive fibrosis and cirrhosis. Given the high prevalence of obesity and diabetes in the Dallas-Fort Worth area and nationwide, MASLD-related cirrhosis is a growing public health concern.
• Chronic hepatitis C — Hepatitis C virus (HCV) causes chronic liver inflammation that, untreated, progresses to cirrhosis in approximately 20% to 30% of infected individuals over 20 to 30 years. The advent of highly effective direct-acting antiviral (DAA) medications now allows cure of hepatitis C in more than 95% of cases, but patients who have already developed cirrhosis before treatment still require ongoing monitoring for complications including liver cancer.
• Chronic hepatitis B — Hepatitis B virus (HBV) is a major global cause of cirrhosis. While a vaccine is available, chronic hepatitis B remains prevalent in certain populations and can cause progressive liver damage leading to cirrhosis and hepatocellular carcinoma.

Less Common Causes

• Autoimmune hepatitis — A condition in which the immune system attacks the liver, causing chronic inflammation and fibrosis.
• Primary biliary cholangitis (PBC) — An autoimmune disease that slowly destroys the small bile ducts within the liver, leading to bile buildup, liver damage, and eventually cirrhosis.
• Primary sclerosing cholangitis (PSC) — A chronic disease that causes inflammation and scarring of the bile ducts inside and outside the liver, often associated with ulcerative colitis.
• Hemochromatosis — A genetic condition causing excessive iron absorption and deposition in the liver and other organs.
• Wilson disease — A rare genetic disorder causing copper accumulation in the liver and brain.
• Alpha-1 antitrypsin deficiency — A genetic condition in which abnormal protein accumulates in the liver, causing damage.
• Cardiac cirrhosis — Chronic right-sided heart failure can cause long-standing liver congestion and eventually cirrhosis.
• Drug-induced liver injury — Chronic exposure to certain medications or toxins can cause progressive liver damage.

Risk Factors

• Heavy alcohol use — Consuming more than 2 drinks per day for women or 3 drinks per day for men over an extended period significantly increases cirrhosis risk.
• Obesity and metabolic syndrome — Central obesity, insulin resistance, high triglycerides, and hypertension are major risk factors for MASLD-related cirrhosis.
• Type 2 diabetes — Diabetes independently increases the risk and severity of liver fibrosis in fatty liver disease.
• Viral hepatitis exposure — Intravenous drug use, blood transfusions before 1992, and certain high-risk occupational or sexual exposures increase hepatitis B and C risk.
• Family history — Genetic predisposition plays a role in many causes of cirrhosis, including hemochromatosis, Wilson disease, and susceptibility to alcohol-related and metabolic liver disease.

How Cirrhosis Is Diagnosed

Diagnosing cirrhosis involves a combination of clinical assessment, blood tests, imaging studies, and in some cases, liver biopsy. Because early cirrhosis is often asymptomatic, the diagnosis is frequently made through screening of at-risk patients or incidentally during evaluation for other conditions.

Blood Tests

A comprehensive blood panel provides critical information about liver function and helps stage the severity of cirrhosis:

• Liver function tests (LFTs) — AST, ALT, alkaline phosphatase, and GGT levels may be elevated but can also be normal or only mildly abnormal in established cirrhosis, as the scarred liver may have fewer functioning cells to release these enzymes.
• Albumin — A protein produced exclusively by the liver. Low albumin levels indicate impaired liver synthetic function and are an important marker of cirrhosis severity.
• Bilirubin — Elevated bilirubin indicates the liver's impaired ability to process this pigment and correlates with disease progression.
• INR/Prothrombin time — Measures the liver's ability to produce blood clotting factors. Elevated INR indicates impaired coagulation.
• Complete blood count (CBC) — Low platelet count (thrombocytopenia) is often the earliest laboratory sign of cirrhosis, resulting from portal hypertension and splenic sequestration. Anemia and low white blood cell count may also be present.
• MELD score — The Model for End-Stage Liver Disease score, calculated from bilirubin, creatinine, and INR values, is used to assess cirrhosis severity and prioritize patients for liver transplantation.

Imaging

• Abdominal ultrasound with Doppler — The first-line imaging study for evaluating the liver. Ultrasound can detect changes in liver size and texture (a nodular, shrunken liver is characteristic of advanced cirrhosis), splenomegaly (enlarged spleen), ascites, and portal vein flow abnormalities. Ultrasound is also used as part of hepatocellular carcinoma screening.
• FibroScan (transient elastography) — A non-invasive, office-based technology that measures liver stiffness as a surrogate for fibrosis. FibroScan can detect advanced fibrosis and cirrhosis with high accuracy and is used both for initial diagnosis and for monitoring changes in liver stiffness over time. Dr. John uses FibroScan as a key component of liver disease assessment at Texas Gut Health.
• CT scan or MRI — Cross-sectional imaging provides detailed evaluation of liver morphology, portal vasculature, and potential liver masses. MRI with contrast is particularly useful for characterizing liver lesions detected on surveillance ultrasound.

Upper Endoscopy (Variceal Screening)

An upper endoscopy (EGD) is a critical part of cirrhosis evaluation. All patients with newly diagnosed cirrhosis should undergo endoscopic screening for esophageal and gastric varices — enlarged, fragile veins caused by portal hypertension that can rupture and cause life-threatening bleeding. The size and appearance of the varices determine whether preventive treatment (such as beta-blocker medication or endoscopic variceal ligation) is needed.

Liver Biopsy

While non-invasive methods have reduced the need for liver biopsy, it remains the gold standard for confirming cirrhosis, determining the cause of liver disease (when unclear from other testing), and assessing the degree of inflammation and fibrosis. Liver biopsy may be performed percutaneously (through the skin) or via the transjugular route in patients with coagulopathy or ascites.

Treatment Options

There is no single cure for cirrhosis, but effective treatment of the underlying cause, management of complications, and appropriate monitoring can significantly slow disease progression, improve quality of life, and extend survival. The treatment approach depends on the cause of cirrhosis, whether it is compensated or decompensated, and the specific complications present.

Treating the Underlying Cause

• Alcohol cessation — For alcohol-related cirrhosis, complete and permanent abstinence from alcohol is the single most important treatment. Even in patients with established cirrhosis, stopping alcohol can improve liver function, reduce portal pressure, prevent further damage, and improve survival. Dr. John can help connect patients with alcohol cessation resources and support programs in the Dallas-Fort Worth area.
• Antiviral therapy for hepatitis B and C — Hepatitis C can now be cured in more than 95% of patients with an 8 to 12-week course of direct-acting antiviral medications, even in patients with compensated cirrhosis. Hepatitis B can be effectively suppressed with long-term antiviral therapy (tenofovir or entecavir). Treating these viral infections halts liver inflammation and can prevent further fibrosis progression.
• Weight loss and metabolic management for MASLD — For patients with fatty liver disease-related cirrhosis, a sustained weight loss of 7% to 10% of body weight through dietary modification and exercise can improve liver inflammation and fibrosis. Management of associated conditions including diabetes, hypertension, and hyperlipidemia is also essential. Newer medications such as resmetirom (Rezdiffra), the first FDA-approved drug for MASH with liver fibrosis, represent an emerging treatment option.
• Immunosuppressive therapy for autoimmune hepatitis — Corticosteroids and azathioprine are used to suppress the immune-mediated liver damage in autoimmune hepatitis.

Managing Complications

• Ascites management — First-line treatment includes sodium restriction (less than 2,000 mg per day) and diuretic medications (typically spironolactone with or without furosemide). For refractory ascites that does not respond to medical therapy, therapeutic paracentesis (removal of ascitic fluid with a needle) or TIPS (transjugular intrahepatic portosystemic shunt) may be necessary.
• Hepatic encephalopathy treatment — Lactulose (an osmotic laxative that reduces ammonia absorption in the colon) and rifaximin (a non-absorbed antibiotic that reduces ammonia-producing bacteria) are the mainstays of hepatic encephalopathy prevention and treatment.
• Variceal bleeding prevention and treatment — Non-selective beta-blockers (propranolol, nadolol, or carvedilol) reduce portal pressure and are used for primary prevention of variceal bleeding. Endoscopic variceal ligation (banding), performed during upper endoscopy, is used for both prevention and treatment of esophageal variceal bleeding.
• Hepatocellular carcinoma (HCC) screening — All patients with cirrhosis require surveillance for liver cancer with abdominal ultrasound and alpha-fetoprotein (AFP) blood test every 6 months. Early detection of HCC allows for curative treatments including surgical resection, ablation, or liver transplantation.
• Spontaneous bacterial peritonitis (SBP) prevention — Patients with cirrhosis and ascites are at risk for spontaneous infection of the ascitic fluid. Prophylactic antibiotics may be prescribed for high-risk patients.

Liver Transplantation

For patients with decompensated cirrhosis who are not responding to medical management, liver transplantation may be the only option for long-term survival. Dr. John works closely with liver transplant centers in the Dallas-Fort Worth area to ensure timely referral and evaluation for patients who may benefit from transplantation. The decision to pursue transplant evaluation is based on the MELD score, the presence and severity of complications, and the patient's overall health and candidacy for major surgery.

Living With Cirrhosis

A diagnosis of cirrhosis is life-changing, but with proper medical management and lifestyle modifications, many patients with compensated cirrhosis can maintain a good quality of life for years. Key strategies for living well with cirrhosis include:

• Complete avoidance of alcohol — Regardless of the cause of cirrhosis, all patients with cirrhosis should abstain completely from alcohol, as even small amounts can accelerate liver damage.
• Nutritional optimization — Malnutrition is common in cirrhosis and worsens outcomes. A diet adequate in protein (1.2 to 1.5 grams per kilogram of body weight daily) and calories is important to prevent muscle wasting. Small, frequent meals and a late-evening snack help maintain energy levels. Sodium restriction (less than 2,000 mg daily) is important for patients with ascites.
• Medication safety — The cirrhotic liver has reduced ability to metabolize medications. Avoid acetaminophen (Tylenol) in doses exceeding 2,000 mg per day, and avoid nonsteroidal anti-inflammatory drugs (NSAIDs such as ibuprofen and naproxen), which can worsen kidney function and increase bleeding risk. Always consult your gastroenterologist before taking new medications, including over-the-counter and herbal supplements.
• Vaccinations — Patients with cirrhosis should receive hepatitis A and hepatitis B vaccines (if not already immune), annual influenza vaccine, pneumococcal vaccine, and COVID-19 vaccines, as their immune systems are compromised.
• Regular monitoring — Adherence to your gastroenterologist's recommended surveillance schedule — including blood tests, liver cancer screening, and endoscopic variceal surveillance — is essential for early detection and management of complications.
• Exercise — Regular, moderate physical activity (walking, swimming, light resistance training) helps maintain muscle mass, improve energy, and support overall health. Exercise programs should be tailored to the individual's functional capacity.

Dr. John and the team at Texas Gut Health provide ongoing, comprehensive cirrhosis management at our Sachse, TX office, conveniently serving patients from Sachse, Garland, Richardson, Plano, Wylie, Murphy, and the greater Dallas-Fort Worth area.

Frequently Asked Questions